Syndax Pharmaceuticals Q2 EPS $(0.64) Beats $(0.73) Estimate
Portfolio Pulse from bharat@benzinga.com
Syndax Pharmaceuticals reported Q2 losses of $(0.64) per share, beating the analyst consensus estimate of $(0.73) by 12.33%. However, this is a 3.23% increase in losses compared to the same period last year.
August 04, 2023 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Syndax Pharmaceuticals' Q2 losses were less than expected, but increased compared to last year.
While Syndax Pharmaceuticals beat the consensus estimate, the increase in losses compared to the same period last year could potentially offset any positive sentiment. The impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100